Sorasiba^TM

Indication:
Sorasiba^TM is indicated for the treatment of:
• Patients with unresectable hepatocellular carcinoma (HCC).
• Patients with advanced renal cell carcinoma (RCC).
• Patients with Differentiated Thyroid Carcinoma (DTC).

Dosage & Administration:
The recommended daily dose of Sorasiba^TM is 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal). Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. It is recommended that Sorafenib should be administered without food or with a low or moderate fat meal. If the patient intends to have a high-fat meal, Sorafenib tablets should be taken at least 1 hour before or 2 hours after the meal. The tablets should be swallowed with a glass of water. Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction of Sorasiba^TM. When dose reduction is necessary, the Sorasiba^TM dose may be reduced to 400 mg once daily. If additional dose reduction is required, Sorasiba^TM may be reduced to a single 400 mg dose every other day. Or, as directed by the registered physicians

Preparation:
Sorasiba^TM Tablet: Each box contains 12 tablets in Alu-Alu blister pack.